Broccoli sprouts powder could improve serum triglyceride and oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial
Introduction
Type 2 diabetes is associated with dyslipidemia and increased lipid peroxidation, key factors promoting atherosclerosis in these patients [1], [2]. Despite availability of multiple interventions, studies show a rising trend in the occurrence of the diabetes complications [3]. Several nutraceuticals such as antioxidant phytochemicals used in clinical trials had favorable effects in the prevention of pathogenesis of diabetes mellitus and its complications [4], [5]. Broccoli sprouts are rich source of health promoting compounds including glucosinalates and isothiocyanates [6], [7], [8]. Animal studies have reported that young broccoli sprout improved lipid profiles [9], [10]. A key bioactive component in broccoli sprout is sulforaphane (1-isothiocyanate-4-methylsulfinylbutane) which is the most potent inducer of the endogenous antioxidant defense [11], [12]. Recently a phase 1 study revealed that consuming fresh broccoli sprouts for one week increased HDL-C, and decreased total cholesterol, LDL-C and some biomarkers of oxidative stress [13]. Short duration of intervention, small sample size and lack of control group were some limitations of this study. The effects of broccoli sprout on lipid profile abnormalities and oxidized LDL/LDL-C ratio as cardiovascular disease risk factors in diabetic patients, has not yet been determined. We therefore conducted this trial to investigate the effect of broccoli sprouts powder on fasting blood glucose, oxidized-LDL/LDL-C ratio, lipid profiles and other lipid related parameters such as atherogenic index of plasma, in type 2 diabetic patients.
Section snippets
Patients and study design
This is a parallel, randomized, double-blind and placebo controlled clinical trial, conducted between March and July 2010. Ethics approval was obtained from the ethical committee of the Research Institute for Endocrine Science of the Shahid Beheshti University of Medical Sciences. The trial has been registered in the Iranian Registry of Clinical Trials at http://www.irct.ir with the following identification: IRCT138901181640N2. The results have been reported according to Consolidated Standards
Results
Of eighty-one randomized patients, seventy-two completed the study [10 g/d BSP (n = 23), 5 g/d BSP (n = 26), placebo (n = 23)] were included in the analysis (Fig. 1). No significant differences between groups were seen for age, sex, weight, and body mass index, duration of diabetes and antidiabetic drugs; nor were there any significant differences in the clinical variables measured between the patients in the 3 treatment groups at baseline (Table 1). Mean dietary intakes of participants at baseline and
Discussion
In the current study, supplementation with 10 g/d BSP in type 2 diabetic patients for 4 weeks had favorable effects on most typical diabetic dyslipidemia and lipid related parameters, as risk factors for cardiovascular disease in these patients.
Hypertriglyceridemia is a common form of dyslipidemia that is frequently associated with coronary heart disease (CHD) [18]. One-mmol/l increase in serum triglycerides has been independently related with 14% and 37% increased risk of CHD in men and women,
Conflict of interest
There are no conflicts of interest.
Acknowledgments
This study was funded by the Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The authors express appreciation to the participants of this study and would like to acknowledge Ms. N. Shiva for language editing of the manuscript. None of the authors had any personal or financial conflicts of interest. The project was designed and implemented by Z.B and P.M. Data were analyzed and interpreted Z.B and G.A. P.M, F.H, A.R and F.A prepared the
References (36)
- et al.
Chemical and biological characterisation of nutraceutical compounds of broccoli
J Pharm Biochem Anal
(2006) - et al.
Oral sulforaphane increases phase II antioxidant enzymes in the human upper airway
Clin Immunol
(2009) - et al.
Antioxidant function of sulforaphane: a potent inducer of phase 2 detoxyfication enzymes
Food Chem Toxicol
(1999) - et al.
CONSORT 2010 statement. Updated guidelines for reporting parallel group randomized trials
J Clin Epidemiol
(2010) - et al.
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials
J Am Coll Cardiol
(2005) - et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Lancet
(2004) - et al.
Effect of insulin treatment on plasma oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients
Diabetes Metab
(2006) - et al.
The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo-B-lipoprotein-depleted plasma
Clin Biochem
(2001) - et al.
In vitro binding of bile acids by spinach, kale, brusseles sprouts, broccoli, mustard green, green bell pepper, cabbage and collards
Food Chem
(2007) - et al.
Hypocholesterolemic properties of plant indoles. Inhibition of acyl-CoA:cholesterol acyltransferase activity and reduction of serum LDL/VLDL cholesterol levels by glucobrassicin derivatives
Biochem Pharmacol
(1994)
Effect of the plant compound indole-3-carbinol on hepatic cholesterol homoeostasis
Food Chem Toxicol
Cruciferous indole-3-carbinol inhibits apolipoprotein B secretion in HepG2 cells
J Nutr
Comparison of coenzyme Q10 plasma levels in obese and normal weight children
Clin Chim Acta
Dyslipidemia in type 2 diabetes mellitus
Curr Diab Rep
Type 2 diabetes as a lipid disorder
Curr Mol Med
Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose
Evid Rep Technol Assess
Nutraceutical in diabetes and metabolic syndrome
Cardiovasc Ther
Antioxidant phytochemicals against type 2 diabetes
Br J Nutr
Cited by (91)
Sulforaphane: A nutraceutical against diabetes-related complications
2023, Pharmacological ResearchBeneficial role of broccoli and its active ingredient, sulforaphane in the treatment of diabetes
2023, Phytomedicine PlusPotential effects of Alliaceae and Brassicaceae edible plants on blood glucose levels in patients with type 2 diabetes: A systematic review and meta-analysis of clinical trials
2022, Pharmacological ResearchCitation Excerpt :The limited number of studies evaluating these outcome measurements did not allow us to perform a meta-analysis. Regarding the therapeutic regimen, nine trials considered a monotherapy with Alliaceae or Brassicaceae [44,46,50–52,54,56,57,59], while six studies were conducted on patients receiving a combined therapy of Alliaceae or Brassicaceae plus metformin [45,47–49,53,55]. Finally, one trial evaluated both garlic monotherapy and combination therapy with sulfonylureas [58].
Dietary broccoli improves markers associated with glucose and lipid metabolism through modulation of gut microbiota in mice
2021, NutritionCitation Excerpt :The proliferation of adipocytes treated with sulforaphane for 24 and 48 h is also suppressed during the early stage of adipogenesis [18]. Furthermore, in a randomized clinical trial, broccoli sprout powder (BSP) significantly decreased serum triacylglycerol concentration compared with placebo [19]. ALP, a biochemical indicator that increases during liver diseases [20], decreased in the groups treated with broccoli.
- 1
Address: No. 24 Parvaneh St, Yemen St, Chamran Exp, Tehran 19395-4763, Iran.
- 2
Address: No. 46 Arghavan-e-gharbi St, Farahzadi Blv, Shahrak-e-Ghods. Tehran 19395-4741, Iran.
- 3
Address: No. 46 Ramin-Malakuti St, Patris Lumumba St, Sattar-khan St, Tehran 14155-3316, Iran.